Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2000

The Pharma Closeout tracks 21 deals, $202.0B in disclosed deal value, 19 with a post-close Outcome Score for the year 2000.

Median Critic Score: 71  ·  Median Outcome Score: 64

Best outcome: Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) (95)  ·  Weakest outcome: Celera Genomics Group (PE Corporation) / Paracel Inc. (10)

All 21 deals

• Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) — 2000 · $6.9B · Worked — the deal delivered on its rationale.
• Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) — 2000 · $450M · Worked — the deal delivered on its rationale.
• Pfizer Inc. / Warner-Lambert Company — 2000 · $90.0B · Worked — the deal delivered on its rationale.
• GSK plc / SmithKline Beecham — 2000 · $12.0B · Worked — the deal delivered on its rationale.
• Genzyme General (Genzyme Corporation) / GelTex Pharmaceuticals Inc. — 2000 · $1.0B · Worked — the deal delivered on its rationale.
• American Home Products Corporation / BASF AG (Cyanamid agricultural divestiture) — 2000 · $3.8B · Worked — the deal delivered on its rationale.
• Chiron Corporation / PathoGenesis Corporation — 2000 · $700M · Worked — the deal delivered on its rationale.
• Genzyme Corporation (Genzyme Biosurgery) / Biomatrix Inc. — 2000 · $700M · Largely worked — most objectives met.
• Watson Pharmaceuticals Inc. / Schein Pharmaceutical Inc. — 2000 · $674M · Largely worked — most objectives met.
• Glaxo Wellcome plc / SmithKline Beecham — 2000 · $76.0B · Largely worked — most objectives met.
• Cephalon Inc. / Anesta Corp. — 2000 · $444M · Largely worked — most objectives met.
• Teva Pharmaceutical Industries Ltd. / Novopharm Limited — 2000 · $600M · Largely worked — most objectives met.
• King Pharmaceuticals Inc. / Jones Pharma Incorporated — 2000 · $3.4B · Mixed — partial payoff, real shortfalls.
• Merck & Co. Inc. / Schering-Plough Corporation (joint venture, ezetimibe) — 2000 · Mixed — partial payoff, real shortfalls.
• EyeTech Pharmaceuticals Inc. / Gilead Sciences Inc. (NX-1838 license) — 2000 · $32M · Mixed — partial payoff, real shortfalls.
• Amgen Inc. / Kinetix Pharmaceuticals Inc. — 2000 · $170M · Underwhelmed — fell short of the thesis.
• Endo Pharmaceuticals Holdings Inc. / Algos Pharmaceutical Corporation — 2000 · $250M · Underwhelmed — fell short of the thesis.
• Tyco International Ltd. / Mallinckrodt Inc. — 2000 · $4.2B · Did not work — the deal failed to deliver.
• Celera Genomics Group (PE Corporation) / Paracel Inc. — 2000 · $245M · Did not work — the deal failed to deliver.
• ICN Pharmaceuticals Inc. (corporate restructuring) / ICN three-way split (Ribapharm carve-out) — 2000
• Aventis Pharma AG / Millennium Pharmaceuticals Inc. — 2000 · $450M

← Deal Library  ·  Interactive search  ·  How we score deals